| LBCT.01 - Sun., Nov. 13, 3:45 p.m. | 
Holger Thiele, MD
Herzzentrum Leipzig,
Leipzig, Germany | Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention: AIDA STEMI Trial
Discussant: Alice K. Jacobs, MD, FAHA, Boston, Mass. |
|
Adnan Kastrati, MD
Deutsches Herzzentrum, Munich, Germany
| ISAR-REACT 4
Abciximab Plus Unfractionated Heparin versus Bivalirudin in Patients with Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. The ISAR-REACT 4 Randomized Trial
Discussant: Deepak Bhatt, MD, MPH, FAHA, Boston, Mass.
|
|
 Samuel Z. Goldhaber, MD
Brigham and Women's Hospital, Boston, Mass.
| ADOPT
Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients: Results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) Trial
Discussant: Mary Cushman, MD, MSc, FAHA, Colchester, Va.
|
|
Kenneth W. Mahaffey, MD
Duke Clinical Res Institute, Durham, N.C.
| TRA•CER
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER) Trial
Discussant: Keith A.A. Fox, MB, ChB, Edinburgh, United Kingdom |
|
C. Michael Gibson, MD
Beth Israel Deaconess Medicine Center, Boston, Mass. | ATLAS ACS 2- TIMI 51
Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with Acute Coronary Syndrome
Discussant: Paul W. Armstrong, MD, FAHA, Edmonton, AB, Canada
|
|
|
| LBCT.02 - Mon., Nov. 14, 10:45 a.m. | 
Niteesh K. Choudhry,
MD, PhD
Harvard Medical School, Boston, Mass. | Post-MI FREEE
The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial Discussant: Eric D. Peterson, MD, MPH, FAHA, Durham, N.C. |
|
Richard Lowrie, MD
National Health Service, Greater Glasgow and Clyde, Glasgow, United Kingdom | HOOPS
Pharmacist Intervention to Prevent Hospitalization and Death in Patients with Heart Failure: A Prospective Cluster Randomised Controlled Trial
Discussant: Mariell Jessup, MD, FAHA, Philadelphia, Pa.
|
|
John Spertus,
MD, MPH, FAHA
Mid America Heart Institute, Kansas City, Mo.
| Evidence-Based, Individualized Informed Consent Form
Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients' Experiences with PCI
Discussant: Manesh R. Patel, MD, Durham, N.C.
|
|
Thomas Aversano, MD
Johns Hopkins Medical Institutions, Baltimore, Md. | CPORT E
Outcomes of Non-Primary PCI at Hospitals with and Without On-Site Cardiac Surgery: A Randomized Study
Discussant: Loren F. Hiratzka, MD, FAHA
|
|
| LBCT.03 - Mon., Nov. 14, 3:45 p.m. | 
Peter R. Kowey, MD
MLH Heart Center Lankenau Medical Center,
Wynnewood, PA | ALPHEE
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50, 100 Or 300 Mg OD with Amiodarone as Calibrator for the Prevention of ICD Interventions or Death (ALPHEE)
Discussant: Cynthia M. Tracy, MD, FAHA, Washington, D.C.
|
|
Lucas Boersma, MD, PhD
St. Antonius Hospital, Nieuwegein, Netherlands
| FAST
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: a Multi-center Randomized Clinical Trial
Discussant: A. Marc Gillinov, MD, FAHA, Cleveland, Ohio
|
|
Jens Cosedis Nielsen,
MD, PhD
Aarhus University Hospital, Skejby, Aarhus N, Denmark
| MANTRA-PAF
A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug Therapy as First-Line Treatment in 294 Patients with Paroxysmal Atrial Fibrillation
Discussant: William G. Stevenson, MD, FAHA, Boston, Mass.
|
|
Stuart J. Connolly, MD
Hamilton General Hospital, Hamilton, ON, Canada | PALLAS
The Results of the PALLAS Study: PALLAS was designed to test whether dronedarone could reduce major vascular morbidity and mortality in patients with permanent atrial fibrillation and previous vascular disease or multiple risk factors.
Discussant: Mark Estes III, MD, FAHA, Boston, Mass.
|
|
| LBCT.04 - Tues., Nov. 15, 10:45 a.m. | 
William E. Boden, MD, FAHA
University of Buffalo,
Buffalo, N.Y. | AIM-HIGH
Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy: Results from the AIM-HIGH Trial
Discussant: Philip Barter, MD, PhD, Sydney Nsw, Australia |
|
Lawrence J. Appel,
MD, MPH, FAHA
Johns Hopkins Medical Institutes University,
Baltimore, MD | POWER
Practice-Based Opportunities for Weight Reduction (POWER)
Discussant: Frank Sacks, MD, FAHA, Boston, Mass.
|
|
Stephen J. Nicholls, PhD
Cleveland Clinic,
Cleveland, Ohio | SATURN
Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results
Discussant: Darwin Labarthe, MD, MPH, PhD, FAHA, Chicago, Ill.
|
|
Stephen J. Nicholls, PhD
Cleveland Clinic,
Cleveland, Ohio | Lipid-Modulating Effects of Evacetrapib
Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins
Discussant: Daniel J. Rader, MD, FAHA, Philadelphia, Pa. |
|
| LBCT.05 - Wed., Nov. 16, 10:45 a.m. | 
Duk-Hyun Kang, MD, PhD
Asan Medical Ctr, Seoul, Korea, Republic of
| EASE
Randomized Trial of Early Surgery versus Conventional Treatment for Infective Endocarditis (EASE)
Discussant: Robert S. Higgins, MD, Columbus, Ohio |
|
Alan T. Hirsch, MD
University of Minnesota,
Minneapolis, MN | CLEVER
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes From the CLEVER Study
Discussant: Michael S. Conte, MD, San Francisco, Calif. |
|
Massimo Imazio, MD
Maria Vittoria Hospital,
Torino, Italy
| COPPS Atrial Fibrillation
Colchicine Reduces Post-Operative Atrial Fibrillation. Results of the COPPS Atrial Fibrillation Study
Discussant: Nancy Nussmeier, MD, FAHA, Syracuse, N.Y.
|
|
Jessica L. Mega, MD, MPH
Brigham and Women's Hospital, Boston, Mass.
| ELEVATE-TIMI 56
ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56
Discussant: Lawrence J. Lesko, PhD, Orlando, Fla. |
|
Roberto Bolli, MD, FAHA
University of Louisville,
Louisville, Ky. | SCIPIO
Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial
|
|
